{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:03Z","timestamp":1786980543673,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10096-025-05164-y","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:31:37Z","timestamp":1748593897000},"page":"2019-2031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u03b2-lactam antibiotics vs vancomycin in treating methicillin-sensitive staphylococcus aureus bloodstream infections: a meta-analysis of clinical outcomes"],"prefix":"10.1007","volume":"44","author":[{"given":"Guoliang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghai","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"3","key":"5164_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SY Tong","year":"2015","unstructured":"Tong SY, Davis JS, Eichenberger E et al (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28(3):603\u2013661","journal-title":"Clin Microbiol Rev"},{"key":"5164_CR2","unstructured":"UpToDate. Clinical approach to Staphylococcus aureus bacteremia in adults 2024. Available from: https:\/\/www.uptodate.com\/contents\/clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults"},{"key":"5164_CR3","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"5164_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Measure 20:37\u201346","journal-title":"Educ Psychol Measure"},{"key":"5164_CR5","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:Ed000142","journal-title":"Cochrane Database Syst Rev"},{"key":"5164_CR6","first-page":"7","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"G Wells","year":"2014","unstructured":"Wells G, Shea B, O\u2019Connell J (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute, Ottawa, p 7"},{"key":"5164_CR7","unstructured":"Julian Higgins JT, Jacqueline Chandler, Miranda Cumpston, Tianjing Li, Matthew Page, Vivian Welch (2023) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook."},{"issue":"5","key":"5164_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1086\/314712","volume":"179","author":"VG Fowler Jr","year":"1999","unstructured":"Fowler VG Jr, Kong LK, Corey GR et al (1999) Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 179(5):1157\u20131161","journal-title":"J Infect Dis"},{"issue":"5","key":"5164_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","volume":"82","author":"FY Chang","year":"2003","unstructured":"Chang FY, Peacock JE Jr, Musher DM et al (2003) Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82(5):333\u2013339","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"5164_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1128\/AAC.00700-07","volume":"52","author":"S-H Kim","year":"2008","unstructured":"Kim S-H, Kim K-H, Kim H-B et al (2008) Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 52(1):192\u2013197","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5164_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","volume":"61","author":"JS McDanel","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ et al (2015) Comparative effectiveness of Beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis 61(3):361\u2013367","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5164_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10096-016-2893-4","volume":"36","author":"GE Park","year":"2017","unstructured":"Park GE, Ko JH, Cho SY et al (2017) Empirical combination of a \u03b2-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy. Eur J Clin Microbiol Infect Dis 36(7):1091\u20131096","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5164_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD et al (2011) Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 11:279","journal-title":"BMC Infect Dis"},{"issue":"2","key":"5164_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin DK Jr et al (2007) Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44(2):190\u2013196","journal-title":"Clin Infect Dis"},{"issue":"14","key":"5164_CR15","first-page":"1167","volume":"33","author":"Y Wang","year":"2013","unstructured":"Wang Y (2013) Comparison of resistance in non-methicillin-resistance Staphyclooccus aureus to cefazolin and vancomycin. Chin J Hosp Pharm 33(14):1167\u20131171","journal-title":"Chin J Hosp Pharm"},{"key":"5164_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1564-5","volume":"16","author":"D Wong","year":"2016","unstructured":"Wong D, Wong T, Romney M et al (2016) Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with \u03b2-lactam vs vancomycin empiric therapy: a retrospective cohort study. BMC Infect Dis 16:1\u20139","journal-title":"BMC Infect Dis"},{"issue":"7","key":"5164_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/CCM.0000000000004371","volume":"48","author":"SS Kadri","year":"2020","unstructured":"Kadri SS (2020) Key takeaways from the U.S. CDC\u2019s 2019 antibiotic resistance threats report for frontline providers. Crit Care Med 48(7):939\u2013945","journal-title":"Crit Care Med"},{"issue":"12","key":"5164_CR18","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/cit560","volume":"57","author":"KW McConeghy","year":"2013","unstructured":"McConeghy KW, Bleasdale SC, Rodvold KA (2013) The empirical combination of vancomycin and a \u03b2-lactam for Staphylococcal bacteremia. Clin Infect Dis 57(12):1760\u20131765","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"5164_CR19","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1086\/491714","volume":"42","author":"DL Stevens","year":"2006","unstructured":"Stevens DL (2006) The role of vancomycin in the treatment paradigm. Clin Infect Dis 42(Suppl 1):S51\u2013S57","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5164_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41579-020-00443-1","volume":"19","author":"F Baquero","year":"2021","unstructured":"Baquero F, Levin BR (2021) Proximate and ultimate causes of the bactericidal action of antibiotics. Nat Rev Microbiol 19(2):123\u2013132","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"5164_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1128\/AAC.50.2.428-438.2006","volume":"50","author":"L Cui","year":"2006","unstructured":"Cui L, Iwamoto A, Lian JQ et al (2006) Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50(2):428\u2013438","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5164_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/jac\/38.4.589","volume":"38","author":"AJ Larsson","year":"1996","unstructured":"Larsson AJ, Walker KJ, Raddatz JK et al (1996) The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 38(4):589\u2013597","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"5164_CR23","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A et al (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52(9):3315\u20133320","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5164_CR24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dkab069","volume":"76","author":"X Casta\u00f1eda","year":"2021","unstructured":"Casta\u00f1eda X, Garc\u00eda-De-la-M\u00e0ria C, Gasch O et al (2021) Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis. J Antimicrob Chemother 76(6):1539\u20131546","journal-title":"J Antimicrob Chemother"},{"key":"5164_CR25","doi-asserted-by":"publisher","unstructured":"Kimmig A, Hagel S, Weis S et al (2021) Management of staphylococcus aureus bloodstream infections. Front Med 7. https:\/\/doi.org\/10.3389\/fmed.2020.616524","DOI":"10.3389\/fmed.2020.616524"},{"key":"5164_CR26","doi-asserted-by":"publisher","unstructured":"Lewis PO, Covert KL, Cluck DB (2018) Cefazolin or nafcillin? \u2014a commentary on the optimal treatment of methicillin-susceptible Staphylococcus aureus bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. Ann Infect 2. https:\/\/doi.org\/10.21037\/aoi.2018.10.01","DOI":"10.21037\/aoi.2018.10.01"},{"key":"5164_CR27","doi-asserted-by":"publisher","unstructured":"Nandhini P, Kumar P, Mickymaray S et al (2022) Recent developments in Methicillin-Resistant Staphylococcus aureus (MRSA) treatment: a review. Antibiotics 11(5):606. https:\/\/doi.org\/10.3390\/antibiotics11050606","DOI":"10.3390\/antibiotics11050606"},{"key":"5164_CR28","doi-asserted-by":"publisher","unstructured":"Kerry L, LaPlante Michael J, Rybak (2004) Impact of High-inoculum staphylococcus aureus on the activities of nafcillin vancomycin linezolid and daptomycin alone and in combination with gentamicin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48(12):4665\u20134672. https:\/\/doi.org\/10.1128\/AAC.48.12.4665-4672.2004","DOI":"10.1128\/AAC.48.12.4665-4672.2004"},{"key":"5164_CR29","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05164-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:09:50Z","timestamp":1758719390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05164-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5164"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05164-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}